165 related articles for article (PubMed ID: 29233926)
1. Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph
De Dominici M; Porazzi P; Soliera AR; Mariani SA; Addya S; Fortina P; Peterson LF; Spinelli O; Rambaldi A; Martinelli G; Ferrari A; Iacobucci I; Calabretta B
Cancer Res; 2018 Feb; 78(4):1097-1109. PubMed ID: 29233926
[TBL] [Abstract][Full Text] [Related]
2. Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Porazzi P; De Dominici M; Salvino J; Calabretta B
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573335
[TBL] [Abstract][Full Text] [Related]
3. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract][Full Text] [Related]
5. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
8. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
9. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
10. [In vitro study of BRD4 inhibitor GSK525762A against primary adult common B-cell acute lymphoblastic leukemia cells in vitro].
Ma S; Chen C; Zhu J; Li Y; Wang X; Song X; Cao J; Xu K
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):563-9. PubMed ID: 26304078
[TBL] [Abstract][Full Text] [Related]
11. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
Agirre X; Vilas-Zornoza A; Jiménez-Velasco A; Martin-Subero JI; Cordeu L; Gárate L; San José-Eneriz E; Abizanda G; Rodríguez-Otero P; Fortes P; Rifón J; Bandrés E; Calasanz MJ; Martín V; Heiniger A; Torres A; Siebert R; Román-Gomez J; Prósper F
Cancer Res; 2009 May; 69(10):4443-53. PubMed ID: 19435910
[TBL] [Abstract][Full Text] [Related]
13. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
14. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells.
Feldhahn N; Henke N; Melchior K; Duy C; Soh BN; Klein F; von Levetzow G; Giebel B; Li A; Hofmann WK; Jumaa H; Müschen M
J Exp Med; 2007 May; 204(5):1157-66. PubMed ID: 17485517
[TBL] [Abstract][Full Text] [Related]
15. The Philadelphia chromosome in leukemogenesis.
Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
[TBL] [Abstract][Full Text] [Related]
16. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.
Massimino M; Vigneri P; Stella S; Tirrò E; Pennisi MS; Parrinello LN; Vetro C; Manzella L; Stagno F; Di Raimondo F
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884309
[TBL] [Abstract][Full Text] [Related]
17. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.
Chien WW; Catallo R; Chebel A; Baranger L; Thomas X; Béné MC; Gerland LM; Schmidt A; Beldjord K; Klein N; Escoffre-Barbe M; Leguay T; Huguet F; Larosa F; Hayette S; Plesa A; Ifrah N; Dombret H; Salles G; Chassevent A; Ffrench M
Leuk Res; 2015 Apr; 39(4):453-61. PubMed ID: 25675863
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family.
Rodriguez-Otero P; Román-Gómez J; Vilas-Zornoza A; José-Eneriz ES; Martín-Palanco V; Rifón J; Torres A; Calasanz MJ; Agirre X; Prosper F
Br J Haematol; 2011 Oct; 155(1):73-83. PubMed ID: 21810092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]